Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I4DQ
|
|||
| Former ID |
DAP000359
|
|||
| Drug Name |
Alprostadil
|
|||
| Synonyms |
Prostaglandin E1; alprostadil; 745-65-3; PGE1; Muse; Edex; Caverject; Prostin VR; Alprostadilum; Femprox; Befar; Vitaros; Prostandin; Liprostin; PGE-1; Prink (TN); Befar (TN); Prostavasin; Vasaprostan; MR-256; Minprog; UNII-F5TD010360; Alprostadil(Caverject); CHEMBL495; (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; Prostivas; Lipoprost; 11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid; (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; FemLife; RayVa; Sugiran; Viridal; MR 256; PGE1 Oligomer; BML1-F06; Caverject (TN); Edex (TN); HEI-507; Muse (TN); Prostin VR pediatric (TN); U-10136; Alprostadil (JP15/USP/INN); Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer; (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid; Lipo-alprostadil
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Diabetic foot ulcer [ICD-11: BD54; ICD-9: 707] | Approved | [1] | |
| Erectile dysfunction [ICD-11: HA01.1; ICD-10: N48.4; ICD-9: 302.72, 607.84] | Approved | [2], [3] | ||
| Therapeutic Class |
Vasodilator Agents
|
|||
| Company |
Pfizer Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H34O5
|
|||
| Canonical SMILES |
CCCCCC(C=CC1C(CC(=O)C1CCCCCCC(=O)O)O)O
|
|||
| InChI |
1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
|
|||
| InChIKey |
GMVPRGQOIOIIMI-DWKJAMRDSA-N
|
|||
| CAS Number |
CAS 745-65-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7312, 3139926, 4266050, 7847248, 7978676, 8143220, 8616376, 12013405, 14901054, 14901056, 24887977, 24890439, 24898661, 24898855, 24898994, 26719695, 26752225, 26752226, 39289772, 46386879, 46386882, 46387002, 47216549, 47515087, 47515088, 47810514, 47959471, 48110217, 48184750, 48415538, 49681576, 49699251, 50104916, 50104917, 53790811, 57357853, 57654538, 77812073, 85789478, 91702047, 92126041, 92308647, 92309224, 92309904, 92712130, 93166905, 99300818, 99302336, 103171219, 103914567
|
|||
| ChEBI ID |
CHEBI:15544
|
|||
| ADReCS Drug ID | BADD_D00086 | |||
| SuperDrug ATC ID |
C01EA01; G04BE01
|
|||
| SuperDrug CAS ID |
cas=000745653
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin E2 receptor EP2 (PTGER2) | Target Info | Agonist | [1] |
| Thromboxane A2 receptor (TBXA2R) | Target Info | Modulator | [4] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Renin secretion | ||||
| Pathways in cancer | ||||
| Calcium signaling pathway | ||||
| Platelet activation | ||||
| Reactome | Prostanoid ligand receptors | |||
| G alpha (s) signalling events | ||||
| G alpha (q) signalling events | ||||
| G alpha (12/13) signalling events | ||||
| Thromboxane signalling through TP receptor | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Ovarian Infertility Genes | ||||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Signal amplification | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1882). | |||
| REF 3 | Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77. | |||
| REF 4 | Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.